JHPCY — Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR

—
OTC · Unknown · Unknown · CIK 2071868 · China
Last close
$12.25
Market Cap
$1.58B
52W High
$20.00
52W Low
$11.50
ADV30
3
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 8,953,178,996 7,840,728,800 2,931,717,376 2,457,964,788 76,719,524,314 43,446,769,543 9,382,216,255
Jun 2026 7,315,018,407 6,292,624,516 1,671,272,111 2,183,171,195 70,773,121,999 38,734,324,278 5,783,381,582
Mar 2026 8,140,565,321 7,049,616,182 2,579,989,309 2,282,268,233 71,293,862,441 40,526,883,023 7,146,776,163
Dec 2025 8,441,334,265 7,274,119,633 2,330,380,135 1,959,885,274 69,867,315,774 40,955,482,468 8,070,492,359

Balance + Analyst (yfinance extras)

Retained Earnings
$45,770,698,359
Inventory
$3,042,838,871
Receivables
—
ST Investments
$113,250,586
EBIT TTM
$10,030,243,216
Pretax Income TTM
$10,024,247,688
Interest Exp TTM
$5,995,528
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$32,564,369,408
EBITDA
$9,452,852,224
Free Cash Flow
$6,307,738,624
Enterprise Value
$25,594,558,464
Total Cash
$40,635,797,504
Total Debt
$67,474,744
Shares Out
129,098,800
Trailing EPS
$0.35
Book Value
$1.39
ROE
14.5%
ROA
8.8%
Div Yield
0.48%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 31,629,416,194 8,596,411,752 7,711,054,812 69,867,315,774 8,070,492,359 61,272,068,641 11,235,378,131
Dec 2024 27,984,605,342 6,803,132,569 6,336,527,015 50,135,645,304 4,045,394,571 45,519,861,860 7,422,753,039
Dec 2023 22,819,784,741 4,625,728,312 4,302,435,930 43,784,506,636 2,751,420,194 40,465,795,359 7,643,665,075
Dec 2022 21,275,270,682 3,344,720,696 3,906,375,067 42,370,875,898 3,957,967,303 37,823,560,699 1,265,264,632

Peers — same industry

TickerNameMarket CapLastDaily %
MIN ABERDEEN INTERMEDIATE INCOME FUND $1.58B $13.91 —
ASTH Astrana Health, Inc. $1.58B $31.99 —
REAL TheRealReal, Inc. $1.58B $12.65 —
EZPW EZCORP INC $1.58B $27.00 —
SBCLY Sumitomo Bakelite Co Limited/ADR $1.57B $17.89 —

News headlines (Yahoo Finance, 1h cache)

China’s pharma industry wants to go global. The US could get in its way.
2026-11-16 14:01 · Yahoo
Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Se
2026-11-06 20:15 · Yahoo
From China to the Global Stage: Hengrui Showcases Innovative Research at ESMO Congress 2026, Exploring New Approaches to Oncology Treatment
2026-10-28 03:00 · Yahoo
Hengrui Pharma Reports Steady Growth in the First Nine Months of 2026
2026-10-27 10:04 · Yahoo
Hengrui Pharma Previews ESMO Congress 2026: 64 Research Findings Highlight Continued Progress Across Innovative Pipelines to Advance Clinical Value
2026-10-21 02:09 · Yahoo
Elevar Therapeutics Resubmits New Drug Application to FDA for Combination of Camrelizumab plus Rivoceranib for Use as a First-line Treatment Option for Unresectable or Metastatic Hepatocellular Carcin
2026-10-14 15:16 · Yahoo
Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting
2026-10-01 10:45 · Yahoo
Can Novo's Licensing Strategy Build Its Next Wave of Oral Medicines?
2026-09-30 12:17 · Yahoo
Top China Biopharma Stocks to Watch, According to Bernstein
2026-09-30 06:18 · Yahoo
Novo Nordisk (CPSE:NOVO B) Licensed A Once Weekly Oral GLP 1 GIP Drug
2026-09-29 19:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.